JAK inhibitors such as ruxolitinib have been shown to reduce STAT1 hyperphosphorylation in STAT1 GOF patients, ameliorating not only the CMCC but also symptoms of autoimmunity (8). Here, STAT1 is linked to Autoimmunity.